Reducing infantile anemia: insight on patterns of process and outcome indicators by ethnicity and socioeconomic class during a 10-year intervention program and 5 years after.
Infantile anemia (IA)
Intervention program
Outcome
Process
Yield
Journal
Israel journal of health policy research
ISSN: 2045-4015
Titre abrégé: Isr J Health Policy Res
Pays: England
ID NLM: 101584158
Informations de publication
Date de publication:
05 01 2022
05 01 2022
Historique:
received:
25
04
2021
accepted:
19
12
2021
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
3
5
2022
Statut:
epublish
Résumé
In 2005, Clalit Health Services (CHS), the largest health maintenance organization in Israel, initiated an intervention program aimed at reducing the prevalence rate of infantile anemia (IA). This study evaluated the progress made during the intervention (2005-2014) and its yield 5 years after it ended (2019). The CHS database was retrospectively reviewed twice yearly from 2005 to 2014 for repetitive samples of children aged 9 to 18 months regarding the previous half-year interval, and a single sample in 2019. Data were collected on gender, ethnicity (Jewish/non-Jewish), socioeconomic class (SEC; low/intermediate/high), hemoglobin testing (yes/no), and hemoglobin level (if tested). Excluded were infants with documented or suspected hemoglobinopathy. At study initiation, the rate of performance of hemoglobin testing was 54.7%, and the IA prevalence rate was 7.8%. The performance rate was lower in the Jewish than the non-Jewish subpopulation. The low-SEC subpopulation had a similar hemoglobin testing rate to the high-SEC subpopulation but double the IA prevalence rate. Overall, by the end of the intervention (2014), the performance rate increased to 87.5%, and the AI prevalence rate decreased to 3.4%. In 2019, there was little change in the performance rate from the end of the intervention (88%) and the IA prevalence was further reduced to 2.7%. The non-Jewish and low-SEC subpopulations showed the most improvement which was maintained and even bettered 5 years after the intervention ended. The 10-year IA intervention program introduced by CHS in 2005 led to a reduction in IA prevalence rate to about 3.5% in all sub-populations evaluated. By program end, the results in the weaker subpopulations, which had the highest prevalence of IA at baseline, were not inferior to those in the stronger subpopulations. We recommended to the Israel Ministry of Health to adopt the intervention countrywide, and we challenge other countries to consider similar interventions.
Sections du résumé
BACKGROUND
In 2005, Clalit Health Services (CHS), the largest health maintenance organization in Israel, initiated an intervention program aimed at reducing the prevalence rate of infantile anemia (IA). This study evaluated the progress made during the intervention (2005-2014) and its yield 5 years after it ended (2019).
METHODS
The CHS database was retrospectively reviewed twice yearly from 2005 to 2014 for repetitive samples of children aged 9 to 18 months regarding the previous half-year interval, and a single sample in 2019. Data were collected on gender, ethnicity (Jewish/non-Jewish), socioeconomic class (SEC; low/intermediate/high), hemoglobin testing (yes/no), and hemoglobin level (if tested). Excluded were infants with documented or suspected hemoglobinopathy.
RESULTS
At study initiation, the rate of performance of hemoglobin testing was 54.7%, and the IA prevalence rate was 7.8%. The performance rate was lower in the Jewish than the non-Jewish subpopulation. The low-SEC subpopulation had a similar hemoglobin testing rate to the high-SEC subpopulation but double the IA prevalence rate. Overall, by the end of the intervention (2014), the performance rate increased to 87.5%, and the AI prevalence rate decreased to 3.4%. In 2019, there was little change in the performance rate from the end of the intervention (88%) and the IA prevalence was further reduced to 2.7%. The non-Jewish and low-SEC subpopulations showed the most improvement which was maintained and even bettered 5 years after the intervention ended.
CONCLUSIONS
The 10-year IA intervention program introduced by CHS in 2005 led to a reduction in IA prevalence rate to about 3.5% in all sub-populations evaluated. By program end, the results in the weaker subpopulations, which had the highest prevalence of IA at baseline, were not inferior to those in the stronger subpopulations. We recommended to the Israel Ministry of Health to adopt the intervention countrywide, and we challenge other countries to consider similar interventions.
Identifiants
pubmed: 34986880
doi: 10.1186/s13584-021-00510-9
pii: 10.1186/s13584-021-00510-9
pmc: PMC8734336
doi:
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Informations de copyright
© 2022. The Author(s).
Références
Acta Paediatr. 2013 Sep;102(9):914-9
pubmed: 23772831
Pediatrics. 2000 Apr;105(4):E51
pubmed: 10742372
N Engl J Med. 2020 Feb 13;382(7):674-678
pubmed: 32053307
Infant Behav Dev. 2009 Dec;32(4):366-75
pubmed: 19592115
J Pediatr. 2001 May;138(5):679-87
pubmed: 11343043
BMJ. 1999 Mar 13;318(7185):693-7
pubmed: 10074011
Public Health Nutr. 2001 Apr;4(2):163-72
pubmed: 11299088
Arch Dis Child. 1999 Sep;81(3):247-52
pubmed: 10451399
Nutr Rev. 2013 Jun;71(6):386-401
pubmed: 23731448
J Pediatr. 2013 Nov;163(5):1260-6
pubmed: 23827739
Pediatrics. 2004 Jul;114(1):86-93
pubmed: 15231912
Pediatrics. 2010 Nov;126(5):1040-50
pubmed: 20923825
Pediatrics. 2003 Oct;112(4):846-54
pubmed: 14523176
Public Health Nutr. 2009 Apr;12(4):444-54
pubmed: 18498676
Pediatr Res. 2021 Jan;89(1):63-73
pubmed: 32330927
Pediatrics. 2006 Oct;118(4):e1055-60
pubmed: 16940163
J Pediatr. 1978 Jan;92(1):21-5
pubmed: 338872
J Strength Cond Res. 2011 Dec;25(12):3412-21
pubmed: 22080308
J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):119-29
pubmed: 24135983
Ann Intern Med. 2015 Oct 6;163(7):529-36
pubmed: 26344176
Am J Clin Nutr. 2009 Dec;90(6):1541-51
pubmed: 19828711
Pediatrics. 2015 Apr;135(4):723-33
pubmed: 25825534
Dev Med Child Neurol. 2013 May;55(5):453-8
pubmed: 23464736
Pediatrics. 2015 Oct;136(4):746-52
pubmed: 26347426
BMC Pediatr. 2017 Dec 29;17(1):218
pubmed: 29284437
Pediatr Res. 2003 Feb;53(2):217-23
pubmed: 12538778
Acta Paediatr. 1997 Jul;86(7):683-9
pubmed: 9240873
Hematol Oncol Clin North Am. 1987 Sep;1(3):449-64
pubmed: 3329182
J Pediatr. 1998 Oct;133(4):559-62
pubmed: 9787699
J Pediatr (Rio J). 2012 Jan-Feb;88(1):33-9
pubmed: 22159301
J Nutr. 2008 Dec;138(12):2534-6
pubmed: 19022985